Clinical trial
Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies
NCT00038376 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00038376 |
|---|---|
| Title | Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies |
| Official title | Phase II Study of Interferon Alpha and Isotretinoin in Patients With T-Cell Malignancies |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, T-Cell, Mycosis Fungoides, Hematologic Neoplasms |
| Intervention type | Drug |
| Interventions | Isotretinoin (Accutane), Interferon Alpha |
| Enrollment | 56 |
| Start date | May 8, 1990 |
| Primary completion | Jun 30, 2005 |
| Completion | Jun 30, 2005 |
| First posted | May 31, 2002 |
| Last update posted | Oct 29, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: